Compare Smith & Nephew plc (SNN) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Smith & Nephew plc trades at $30.16 (market cap $12.64B), while YieldMax TSLA Option Income Strategy ETF trades at $25.58. The key difference: Smith & Nephew plc pays a 2.57% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Smith & Nephew plc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| SNN | TSLY | |
|---|---|---|
Market Cap | $12.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $38.70 | $48.25 |
52-Week Low | $28.73 | $25.07 |
Enterprise Value | $15.41B | — |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
TSLY trades at $25.07, down 2.57% over the past day, with a bearish technical outlook from moving averages and oscillators. The ETF maintains a high distribution yield, with weekly dividends averaging around $0.30 per share, though recent news highlights concerns about capped upside relative to Tesla's performance. Key support sits near $25, while resistance is at $26.
The outlook for TSLY is cautious due to its option income strategy limiting capital appreciation. Risks include volatility from Tesla's stock movements and potential erosion of principal from return of capital distributions. Investors seeking high yield may find value, but must weigh the trade-off between income and growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
